For Healthcare Professionals

Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

clipboard-pencil

About the study

This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Healthy post-menopausal women.
  2. Capable of providing informed consent.
  3. Weight of ≥50 kg and a BMI ≥19 and ≤39 kg/m2.
  4. Subjects should be able to communicate with clinic staff.

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Subjects who have a history of allergy or hypersensitivity to letrozole or any of the inactive ingredients.
  2. Subjects who have a history of galactose intolerance, severe hereditary lactase deficiency glucose-galactose malabsorption.
  3. Subjects who have used estrogen or progesterone hormone replacement therapy, thyroid replacement therapy, oral contraceptives, androgens, luteinizing hormone (LH) releasing hormone analogs, prolactin inhibitors, or antiandrogens within prior to Screening.
  4. Subjects who have used: any medications including St. John's wort or any medications or products known to be potent or moderate inhibitors of CYP P450 3A4.
  5. Subjects who have been diagnosed with osteoporosis.
  6. Subjects who have an abnormality at Screening or prior to first dose that in the opinion of the investigator increases the risk of participating in the study.
  7. Subjects who have any clinically significant abnormal physical examination or laboratory safety findings at screening.
  8. Subjects who have relevant diseases or clinically significant abnormal relevant findings at Screening, as determined by medical history, physical examination, laboratory, ECG, DEXA, and breast and pelvic examination.
  9. Subjects who have history of any significant chronic disease.
  10. History of cancer within the past 5 years with the exception of non-melanoma skin cancer.
  11. Subjects who have a history of drug-dependence, and recent history of alcoholism or abuse of alcohol.
  12. Subjects who have received a drug in research or have participated in other clinical trials within 90 days, prior to dosing.
  13. Any other unspecified reason that, in the opinion of the investigator (or designee) or sponsor, makes the subject unsuitable for enrolment.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 00 44 913756230Email iconEmail Study Center

Study Details


Contition

Healthy

Age

18 - 75

Phase

PHASE1

Participants Needed

90

Est. Completion Date

Jan 31, 2025

Treatment Type

INTERVENTIONAL


Sponsor

Rovi Pharmaceuticals Laboratories

ClinicalTrials.gov NCT Identifier

NCT06315205

Study Number

ROV-LEBE-2023-01

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.